Last 47 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 157.56 | 52.85 | 79.24 | 161.75 | 53.69 | — | 62.13 | 13.85 | — | 18.34 | 38.45 | 17.66 | 33.35 | 19.64 | — | — | — | 36.44 | 127.20 | — | 35.90 |
| — | — | +27.6% | +1067.6% | — | — | +61.6% | -21.5% | — | -6.6% | — | — | — | -46.1% | — | — | — | +0.9% | +67.0% | — | +602.2% | |
| P/S Ratio | 1.37 | 1.33 | 1.30 | 1.41 | 1.60 | 1.50 | 1.71 | 1.23 | 1.03 | 2.03 | 2.28 | 2.42 | 2.44 | 3.08 | 2.92 | 2.58 | 3.64 | 4.51 | 5.61 | 4.21 | 4.98 |
| — | -11.4% | -23.8% | +14.5% | +55.0% | -26.1% | -25.0% | -49.1% | -57.7% | -34.0% | -22.0% | -5.9% | -33.1% | -31.8% | -47.9% | -38.9% | -27.0% | -11.5% | -17.1% | -17.5% | -12.0% | |
| P/B Ratio | 1.64 | 1.52 | 1.41 | 1.60 | 1.58 | 1.43 | 1.45 | 1.19 | 0.93 | 1.64 | 1.71 | 2.02 | 1.92 | 2.58 | 2.44 | 2.29 | 3.17 | 4.04 | 4.99 | 3.67 | 3.54 |
| — | +6.1% | -2.3% | +35.2% | +70.1% | -12.8% | -15.3% | -41.2% | -51.8% | -36.3% | -30.0% | -11.7% | -39.3% | -36.2% | -51.1% | -37.8% | -10.7% | +0.4% | +0.9% | -15.0% | -22.2% | |
| P/FCF | 7.26 | 4.55 | 10.07 | 6.40 | 5.03 | 29.16 | 10.74 | 7.45 | 3.48 | 7.00 | 8.24 | 9.59 | 9.73 | 13.01 | 37.32 | 12.12 | 16.26 | 42.33 | 38.34 | 47.75 | 13.48 |
| — | -84.4% | -6.3% | -14.1% | +44.3% | +316.6% | +30.3% | -22.4% | -64.2% | -46.2% | -77.9% | -20.9% | -40.2% | -69.3% | -2.7% | -74.6% | +20.6% | +19.8% | — | +130.2% | -35.1% | |
| EV / EBITDA | 10.36 | 12.02 | 11.48 | 14.35 | 12.92 | 9.89 | 16.29 | 7.00 | — | 9.81 | 15.19 | 10.60 | 14.44 | 11.11 | 37.32 | 29.62 | 18.98 | 18.08 | 28.85 | 46.68 | 19.96 |
| — | +21.5% | -29.6% | +105.1% | — | +0.9% | +7.2% | -34.0% | — | -11.8% | -59.3% | -64.2% | -23.9% | -38.5% | +29.4% | -36.5% | -4.9% | -10.4% | -24.2% | +42.8% | -41.1% | |
| EV / EBIT | 38.66 | 71.42 | 36.43 | 89.28 | 27.01 | 184.65 | 30.32 | 10.95 | — | 11.63 | 29.54 | 15.03 | 26.94 | 15.96 | — | — | 71.45 | 31.44 | 65.99 | 234.01 | 24.00 |
| — | -61.3% | +20.1% | +715.4% | — | +1487.4% | +2.7% | -27.1% | — | -27.1% | — | — | -62.3% | -49.2% | — | — | +197.7% | +25.4% | +35.9% | +473.8% | -60.5% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 79.4% | 77.0% | 79.5% | 79.5% | 80.9% | 77.4% | 79.7% | 78.7% | 76.9% | 75.1% | 71.6% | 73.7% | 75.8% | 71.6% | 69.4% | 64.0% | 69.7% | 70.1% | 77.2% | 75.5% | 72.9% |
| — | -0.5% | -0.3% | +1.1% | +5.1% | +3.1% | +11.3% | +6.8% | +1.6% | +5.0% | +3.2% | +15.1% | +8.6% | +2.1% | -10.0% | -15.2% | -4.3% | -5.3% | +4.8% | +3.3% | -2.1% | |
| Operating Margin | 4.6% | 2.2% | 2.6% | 1.6% | 3.5% | 4.7% | 1.2% | 13.2% | -82.8% | 15.9% | 7.9% | 18.3% | 10.8% | 23.5% | -1.9% | -5.8% | 12.7% | 18.4% | 11.0% | 2.6% | 24.6% |
| — | -52.7% | +121.3% | -87.7% | +104.3% | -70.4% | -85.1% | -27.9% | -865.6% | -32.6% | +510.1% | +418.1% | -15.0% | +27.6% | -117.5% | -317.5% | -48.3% | -28.3% | -32.6% | -81.6% | +64.1% | |
| Net Margin | 1.0% | 2.4% | 1.6% | 0.8% | 3.0% | -2.7% | 2.8% | 8.6% | -85.1% | 10.6% | 5.4% | 13.7% | 6.6% | 15.2% | -12.2% | -5.9% | -0.4% | 11.7% | 4.3% | -3.2% | 13.8% |
| — | +190.4% | -42.3% | -90.3% | +103.6% | -125.2% | -47.0% | -37.6% | -1384.9% | -30.2% | +144.1% | +333.6% | +1700.7% | +29.6% | -381.9% | -82.3% | -103.0% | -16.6% | -50.4% | -129.1% | -87.5% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 1.0% | 0.7% | 0.4% | 0.2% | 0.7% | -0.6% | 0.6% | 2.1% | -17.6% | 2.1% | 1.0% | 2.9% | 1.3% | 3.3% | -2.5% | -1.3% | -0.1% | 2.7% | 0.9% | -0.7% | 2.5% |
| — | +212.7% | -29.1% | -89.0% | +104.2% | -129.2% | -40.1% | -28.2% | -1430.0% | -34.8% | +140.2% | +323.5% | +1558.7% | +20.6% | -367.0% | -84.7% | -103.6% | -4.9% | -41.9% | -129.4% | -90.6% | |
| ROA | 0.5% | 0.4% | 0.2% | 0.1% | 0.4% | -0.3% | 0.3% | 1.0% | -9.1% | 1.2% | 0.6% | 1.6% | 0.7% | 1.7% | -1.2% | -0.6% | -0.0% | 1.1% | 0.3% | -0.3% | 1.3% |
| — | +222.3% | -23.1% | -87.7% | +104.2% | -126.5% | -46.1% | -34.8% | -1383.0% | -30.4% | +146.6% | +370.5% | +1864.5% | +53.3% | -454.1% | -97.8% | -103.0% | -24.9% | -57.5% | -125.7% | -89.4% | |
| ROIC | 2.3% | 0.4% | 0.4% | 0.2% | 0.5% | 0.6% | 0.1% | 1.6% | -8.6% | 1.6% | 0.8% | 1.9% | 1.0% | 2.2% | -0.2% | -0.5% | 1.1% | 1.6% | 0.9% | 0.3% | 2.1% |
| — | -37.5% | +179.0% | -85.2% | +105.3% | -65.5% | -83.0% | -14.5% | -963.8% | -25.6% | +560.2% | +472.4% | -7.9% | +39.5% | -117.6% | -294.3% | -47.9% | -31.4% | -29.0% | -80.9% | +33.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.66 | 0.61 | 0.63 | 0.66 | 0.58 | 0.83 | 0.80 | 0.82 | 0.86 | 0.74 | 0.65 | 0.67 | 0.71 | 0.77 | 0.81 | 0.99 | 1.07 | 1.10 | 1.41 | 1.55 | 0.77 |
| — | -26.4% | -21.1% | -20.1% | -32.0% | +13.0% | +22.2% | +21.9% | +21.1% | -4.0% | -19.9% | -31.6% | -33.5% | -30.1% | -42.3% | -36.3% | +38.2% | +37.5% | +68.7% | +77.0% | -15.9% | |
| Debt / EBITDA | 3.65 | 16.12 | 15.84 | 18.52 | 15.44 | 17.63 | 27.48 | 13.90 | — | 13.77 | 18.39 | 11.35 | 16.33 | 10.53 | 37.86 | 37.22 | 19.80 | 15.96 | 26.75 | 65.32 | 14.92 |
| — | -8.5% | -42.4% | +33.2% | — | +28.0% | +49.5% | +22.5% | — | +30.7% | -51.4% | -69.5% | -17.6% | -34.0% | +41.5% | -43.0% | +32.7% | +15.5% | +19.4% | +187.8% | -37.0% | |
| Current Ratio | 4.54 | 5.04 | 4.73 | 4.54 | 5.26 | 2.38 | 2.41 | 2.40 | 2.25 | 6.82 | 5.81 | 5.24 | 4.78 | 3.94 | 3.81 | 3.37 | 4.06 | 3.95 | 2.19 | 1.66 | 3.64 |
| — | +111.8% | +96.0% | +89.0% | +133.4% | -65.1% | -58.5% | -54.1% | -52.8% | +73.0% | +52.5% | +55.3% | +17.7% | -0.2% | +74.3% | +102.9% | +11.4% | +14.0% | -29.5% | -35.4% | -52.3% | |
| Quick Ratio | 3.28 | 3.94 | 3.35 | 3.28 | 3.78 | 1.91 | 1.99 | 2.00 | 1.89 | 5.70 | 4.78 | 4.17 | 3.74 | 3.10 | 2.87 | 2.72 | 3.32 | 3.20 | 1.85 | 1.47 | 3.34 |
| — | +106.5% | +68.4% | +63.8% | +100.5% | -66.6% | -58.3% | -52.0% | -49.6% | +84.3% | +66.5% | +53.0% | +12.8% | -3.1% | +55.3% | +84.8% | -0.7% | +0.5% | -34.6% | -36.4% | -51.1% | |
| Interest Coverage | 2.16 | 1.19 | 2.57 | 1.17 | 3.61 | 0.41 | 2.72 | 7.66 | -28.79 | 12.72 | 4.91 | 10.75 | 5.60 | 10.62 | -1.86 | -0.77 | 1.12 | 3.39 | 1.60 | 0.33 | 4.21 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PCRX stock.
Pacira BioSciences, Inc.'s current P/E is 157.6x. The average P/E over the last 4 quarters is 86.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Pacira BioSciences, Inc.'s current operating margin is 4.6%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Pacira BioSciences, Inc.'s business trajectory between earnings reports.